Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

COGT

Phase 2

Bezuclastinib (CGT9486) (KIT exon 17 inhibitor)

NASM (Non-Advanced Systemic Mastocytosis)

July 2025

SUMMIT trial. 2/22/24- Initiated Part 2. 12/9/24- Long term follow-up results from OLE patients at ASH. 2/27/25- Reported expanded clinical results from OLE portion of SUMMIT. Data presented AAAAI/WAO '25. Part 2 topline results in July 2025.

Data readout

AGEN

Phase 2

Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034)

Advanced MSS colorectal cancer (MSS CRC)

H1 2025

Big Mover: ACTIVATE study. 4/12/24- 12mth & 18mth data. 4/24/24- Presentation Ph1b sub-analysis at ASCO '24. 7/18/24- EoP2 meeting results, FDA discouraged accelerated approval. EU agency meeting in Q3 2024. Present Ph2 data at med. conf. in H2 2024. 11/12/24 - Advancing to Ph3. Additional data in H1 2025.

Additional data readout

INSM

PDUFA

Brensocatib (DPP1 inhibitor)

NCFBE (Non-Cystic Fibrosis Bronchiectasis)

August 12, 2025

WILLOW/ASPEN studies. Enrollment completed. Ph2 WILLOW subgroup analysis data at ATS 2023. 5/28/24 Positive Ph3 ASPEN data & investor call. 7/3/24 Additional ASPEN data at 7th WBC '24. NDA in Q4 '24. 2/6/25- Granted priority review. PDUFA target action date August 12, 2025.

Approval decision

Meeting

Biomedical meeting

World Conference on Lung Cancer (WCLC)

Lung Cancer

August 13, 2025

WCLC Full Abstract release on August 13, 2025, for all except that are embargoed until the time of presentation on September 6-9, 2025. See details in https://wclc.iaslc.org/important-dates/

Abstract release

ATAI

Phase 2b

RL-007

Cognitive Impairment Associated with Schizophrenia (CIAS)

Mid-2025

3/17/25- Ph2b proof-of-concept study ongoing. Topline results in mid-2025.

Data readout

PRTA

Phase 1

PRX012

Alzheimer’s disease

Mid-2025

ASCENT Trials. 11/12/24- Multiple clinical readouts in mid-2025. Poster presentation highlighting clinical trial design in CTAD 2024.

Data readout

TARA

Phase 2

TARA-002

Non-Muscle Invasive Bladder Cancer (NMIBC)

Mid-2025

ADVANCED-1, ADVANCED-2 trials. 09/23- Initiated ADVANCED-2 trial. 12/5/24- Reported Ph2 open-label trial data and presented at SUO '24. 3/5/25- 12mt initial data by mid-2025.

Data readout

HRMY

Phase 3

Zygel (ZYN002 CBD Gel)

FXS (Fragile X Syndrome)

mid-2025

RECONNECT Study. 4/12/23- Encouraging interim data at 55th Gatlinburg Conference. 10/11/23- Asset acquired. 2/22/24- Complete enrollment in Q1 2025 w/ topline data in mid-2025

Data readout

PMVP

Phase 2

Rezatapopt/ PC14586 (p53 reactivator)

Metastatic Solid Tumors w/ TP53 Y220c Mutation

Mid-2025

Collab. w/ Merck. PYNNACLE monotherapy study. 3/18/24 Ph1 data presented at SGO '24. 3/27/24- First patient dosed in Ph2 trial. 3/3/25- Enrollment ongoing w/ interim analysis in mid-2025 and NDA submission by YE 2026.

Data readout

BCTX

Phase 3

Bria-IMT™ (SV-BR-1-GM)

Orbital "Eye-Bulging" metastatic breast cancer tumor

Mid-2025

PREVAIL trial. 9/11/24- Reported OS data. Complete Ph3 enrollment in mid-2025 & interim data in H2 2025. 10/22/24- Reported 1-year survival rate from Ph2 study. 12/2/24- DSMB recommended continuation of Ph3 study. 12/13/24- Updated Ph2 data presented via poster at SABCS '24.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20